Eupraxia Pharmaceuticals Inc (EPRX) — Cash Flow-to-Debt Ratio
Eupraxia Pharmaceuticals Inc (EPRX) has a Cash Flow-to-Debt Ratio of -0.83x as of September 2025, meaning its operating cash flow of CA$-4.51 Million could theoretically repay -1% of its total liabilities (CA$5.43 Million) in one year. See Eupraxia Pharmaceuticals Inc (EPRX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eupraxia Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Eupraxia Pharmaceuticals Inc across 8 annual periods. Also explore how fast is Eupraxia Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eupraxia Pharmaceuticals Inc (2017–2024)
Year-by-year debt coverage analysis for Eupraxia Pharmaceuticals Inc. For market capitalisation and broader financial context, see EPRX market cap.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -6.72x | CA$-29.99 Million | CA$4.46 Million | ▼ -515.0% |
| 2023 | -1.09x | CA$-27.92 Million | CA$25.55 Million | ▲ +15.5% |
| 2022 | -1.29x | CA$-18.78 Million | CA$14.51 Million | ▼ -3.1% |
| 2021 | -1.25x | CA$-14.64 Million | CA$11.67 Million | ▼ -7081.0% |
| 2020 | -0.02x | CA$-403.93K | CA$23.12 Million | ▲ +92.8% |
| 2019 | -0.24x | CA$-5.17 Million | CA$21.42 Million | ▲ +58.4% |
| 2018 | -0.58x | CA$-8.32 Million | CA$14.34 Million | ▲ +91.9% |
| 2017 | -7.20x | CA$-5.30 Million | CA$735.82K | — |